百济神州(688235)今日盘中股价大涨5.65%,引起了市场广泛关注。消息面上,该公司与MSN公司就围绕首个自主研发新药泽布替尼的专利纠纷达成和解,为其核心产品保驾护航,提振了市场对公司长期发展前景的信心。
目前,百济神州和MSN达成的和解协议规定,MSN未来不得在2037年6月15日之前销售泽布替尼仿制药。通过此协议,百济神州在泽布替尼专利方面具有较长期的独家期限,在一定程度上消除了来自仿制药阵营的压力,提振了投资者对公司的信心。
泽布替尼是百济神州创新研发的首个最佳用药BTK抑制剂,已在全球70多个国家和地区获批上市用于治疗多种B细胞恶性肿瘤,曾一度是公司营收主力。此次和解协议确保百济神州未来几年能继续从这一核心产品中获得收益,为其持续创新投入提供保障。公司表示将继续推进创新药物研发,并依赖专利体系保护知识产权,也将把重点放在扩大新药在全球的可及性上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.